PALB2 and breast cancer: However, when compared to our findings, we found that all the PALB2-germline mutations in our PALB2-associated breast cancers were high risk frameshift, stopgain or splicing mutations, while most of the PALB2-germline mutations in PALB2-NULL patients (7/10) were moderate missense mutation (Lee et al., 2018).